Hello Subs!
This podcast provides an overview of Olema Oncology (OLMA) and previews the pending results from Roche’s persevERA study in 1L HR+/HER2- mBC, which will have a profound impact on OLMA’s stock.
In the podcast, I make reference to the following images:
Fig. 1: Why are we talking about this?
